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DObjective: The aim of this study was to evaluate the long-term fate of the cryopreserved mitral homograft
focusing on structural valve deterioration.
Methods: Homograft replacement of the mitral valve was performed in 106 patients. The causes of mitral dis-
ease were rheumatic disease (n ¼ 75), endocarditis (n ¼ 24), and others (n ¼ 7). There were 40 partial homo-
grafts and 66 total homografts.
Results: Mean follow-up was 9.3þ4.7 years (up to 17.8 years). There were 5 early (<3 months) and 15 late
deaths. There have been 5 early (<3 months) and 30 late reoperations. Five patients had endocarditis, and 5 pa-
tients had an ischemic/hemorrhagic event. Compared with baseline, follow-up echography showed progression
of mitral regurgitation grade (from 0.4 to 1.3; P<.001) with stenosis (elevated gradient: from 3.9 to 7.0 mm Hg;
P<.001) and decreased valve area (from 2.3 to 1.7 cm2, P<.001). Freedom from structural valve deterioration
was 90%, 76%, and 65% at 5, 10, and 15 years, respectively. Structural valve deterioration was more frequent in
total homografts (P¼ .018 vs partial homografts) and in case of pregnancy (P¼ .016 vs no pregnancy). Stenosis
related to structural valve deterioration was more pronounced for age less than 40 years (P ¼ .03) and ring size
30 mm or less (P ¼ .002). Pathologic analysis of the explanted homografts almost invariably showed dense
fibrosis with calcification and no cellularity.
Conclusions: Mitral homografting was accomplished with early echographic results similar to those of valve
repair. Structural valve deterioration produced mixed stenosis with insufficiency, and its incidence was compa-
rable to that of bioprostheses structural valve deterioration. An improvement in the preservation mode of valvu-
lar homografts is warranted. (J Thorac Cardiovasc Surg 2012;144:313-20)Supplemental material is available online.
For many years, allogenous transplantation of the mitral
valve has remained an open question.1 In the beginning of
the 1990s, significant advances were reported, such as tri-
cuspid valve replacement with a mitral homograft2 and par-
tial mitral valve replacement with a homograft segment.3
Isolated cases of complete mitral homograft replacement4
were then reported, including the description from our
group of an original technique based on a side-to-side sutur-
ing of the homograft papillary muscles with multiple inter-
rupted stitches together with prosthetic ring implantation.5
In 1996, the technique applied in a series of 43 patients
proved to be safe and reproducible.6 Pitfalls that were re-
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The Journal of Thoracic and Calearning phase have been addressed.6 More recently, clini-
cal and echographic results at intermediate-term follow-
up (mean: 4.3 years) in a series of 104 patients were
reported.7 The aim of the present study was to evaluate
the durability of the cryopreserved mitral homograft valve
over a period extending up to 18 years focusing on structural
valve deterioration.MATERIALS AND METHODS
Patients
From February 1993 to May 2003, 106 patients (female, n ¼ 67; male,
n ¼ 49) underwent mitral homograft replacement. The mean age was
38.1  15 years (10–71 years) with 11 patients aged less than 18 years.
Electrocardiography showed sinus rhythm in 87 patients and chronic atrial
fibrillation in 19 patients. The cause of mitral valve disease was rheumatic
valve disease (n ¼ 75); bacterial endocarditis (n ¼ 24), including 5 cases
involving a previously diseased mitral valve (rheumatic valve disease:
n ¼ 3, Barlow disease: n ¼ 2); autoimmune disorder (n ¼ 4) (systemic lu-
pus: n¼ 2, primary antiphospholipid syndrome: n¼ 1, juvenile polyarthri-
tis: n ¼ 1); marasmic endocarditis (n ¼ 1); Barlow disease (n ¼ 1); and
congenital stenosis (n ¼ 1). Twenty-six patients had previously undergone
mitral valve operations: repair (n ¼ 23) or replacement (n ¼ 3). The ratio-
nale for choosing a homograft was as follows: age less than 18 years
(n¼ 11), woman of childbearing age (n¼ 38), contraindication to oral anti-
coagulation (n ¼ 50), and endocarditis (n ¼ 24).
Surgical Technique
The technical details of mitral homograft insertion have been de-
scribed.7,8 Surgical strategy was based on the extent of valve lesions.rdiovascular Surgery c Volume 144, Number 2 313
Abbreviation and Acronym
MR ¼ mitral regurgitation
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DPartial homograft replacement was performed in 40 cases using an anterior
leaflet patch (n ¼ 10) or a mitral hemivalve with reimplantation of the
corresponding papillary muscle (n ¼ 30). Patients with endocarditis
preferentially underwent partial homograft replacement (16/24).
Complete homograft replacement was achieved in 66 cases. Prosthetic
ring annuloplasty was realized in all patients with a Carpentier-Edwards
Physio Ring (Edwards Lifesciences LLC, Irvine, Calif) (n¼ 72) or flexible
Duran ring (Medtronic, Minneapolis, Minn) (n ¼ 34). Ring size was re-
ported by the intercommissural distance given by the Carpentier-
Edwards obturator or the Duran obturatorþ 2 mm. Mean ring size was
31.4  1.7 mm (28–36 mm). Because of smaller body size in the pediatric
group, ring size in patients aged less than 40 years was smaller than in older
patients (31.1  1.8 vs 31.7  1.7 cm2, P ¼ .04). Likewise, ring size was
smaller in complete than in partial homografts (31.2  1.7 vs 31.8 
1.7 cm2, P ¼ .01).
Associated surgery included aortic valve repair (n ¼ 5) or aortic
valve replacement with a homograft (n ¼ 10), tricuspid valve annulo-
plasty (n ¼ 7) or tricuspid valve replacement with a mitral homograft
(n ¼ 2), pulmonary vein isolation (n ¼ 4), and coronary artery bypass
(n ¼ 1).
Clinical Follow-up
Data were periodically collected at spaced time intervals (5 years). In
addition, cross-sectional analysis in a retrospective manner was carried out
over the second semester of the year 2010. Clinical follow-up was obtained
by physical examination or by phone directly from the patient or the pa-
tient’s general practitioner or cardiologist.
Echocardiography
Baseline echocardiography was performed immediately after the oper-
ation at the time of discharge. Follow-up echocardiography was obtained at
the latest periodical examination or immediately before redo surgery. Mi-
tral valve regurgitation was graded according to jet extension. Transvalvu-
lar gradient was measured by Doppler, and surface valve area was
calculated according to the Hattle formula.
Structural Valve Deterioration
Structural valve deterioration was defined according to the guide-
lines9 as intrinsic changes to the homograft, such as calcification
and tear leading to dysfunction. Early technical failure and endocardi-
tis were excluded. Diagnosis of structural deterioration relied on the
aspect of the valve at reoperation and on echocardiographic surveil-
lance. It was considered when echography showed leaflet thickening/
calcification together with severe dysfunction: regurgitation grade 3
or 4, mean gradient greater than 10 mm Hg, or valve area less than
1 cm2.
Statistical Analysis
Descriptive data for continuous variables were presented as means
with standard deviation. Patient groups were compared by chi-square
test for categoric values and Student t test for continuous variables. Sur-
vival, freedom from reoperation, and freedom from structural deteriora-
tion were estimated according to the Kaplan–Meier method. When
structural valve deterioration was detected by echocardiography, the
date of the examination was used for constructing the Kaplan–Meier
curve.314 The Journal of Thoracic and Cardiovascular SurgRESULTS
Follow-up was 96.2% complete (4 patients lost to
follow-up). The mean duration of the observation period
was 9.3  4.7 years (0.4–17.8 years).Survival
There were 5 early deaths (4.7%) in the perioperative
period (<3 months). Fifteen other patients ultimately
died. Cardiac causes of death were congestive heart fail-
ure (n ¼ 2), pulmonary embolus (n ¼ 1), and death at re-
operation (n ¼ 3). The other causes of mortality were
cancer (n ¼ 6) (laryngeal n ¼ 1, lung n ¼ 2, digestive
n ¼ 2, and urogenital n ¼ 1), human immunodeficiency
virus-related infection (n ¼ 1), trauma with cerebral hem-
orrhage (n ¼ 1), and degenerative neuropathy (n ¼ 1).
Survival according to the Kaplan–Meier estimate was
88%, 85%, and 80% at 5, 10, and 15 years, respectively
(Figure 1).Reoperation
Incidence. There were 5 early reoperations within
3 months for mitral homograft failure. All were technically
related: restriction due to improper papillary muscle posi-
tioning (n ¼ 3), leaflet suture dehiscence (n ¼ 1), and
chordal rupture due to erosion by the suture material
(n ¼ 1).6,7 There were 30 late reoperations (>3 months)
after a mean period of 7.6 years (1.3–13.9 years) for an
overall 67.0% freedom of reoperation. Late reoperations
were primarily indicated for degeneration of the mitral
homograft (n ¼ 23), bacterial endocarditis (n ¼ 5),
and aortic valve disease (n ¼ 2). Kaplan–Meier freedom
from reoperation was 88%, 80%, and 64% at 5, 10, and
15 years, respectively (Figure 1).
Determinants of reoperation were studied for age (<40 vs
>40 years), homograft technique (total vs partial homo-
graft), prosthetic ring size (30 mm vs larger size), associ-
ated aortic valve surgery, endocarditis as primary
indication, and pregnancy. There was no statistically signif-
icant difference among subgroups (Table E1).
When specifically considering patients in the pediatric
age group (<18 years), there was a trend toward a higher
rate of reoperation (6/11 or 54.5%) (P ¼ .11). Likewise,
the use of a 28-mm prosthetic ring size was associated
with a higher risk of reoperation (P ¼ .003 vs larger size
rings).
Technique and results. Reoperation after mitral homo-
graft replacement was not particularly challenging. The mi-
tral homograft was replaced in all cases except in 1 patient
with no dysfunction of an anterior leaflet homograft patch
who required aortic valve replacement. In another reopera-
tion for aortic valve dysfunction at 10 years, prophylactic
replacement of a mildly dysfunctioning mitral homograft
was carried out.ery c August 2012
FIGURE 1. Kaplan–Meier estimate of survival, freedom from reopera-
tion, and freedom from structural valve deterioration in 106 patients with
a cryopreserved mitral homograft valve.
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moval, and then the whole mitral homograft valve was ex-
cised. Because of the extent of calcifications, it was
seldom possible to retain basal chordae of the homograft.
Mitral valve replacement was performed with a mechanical
prosthesis in 20 cases and a bioprosthesis in 14 cases. Asso-
ciated aortic valve replacement was realized in 7 cases for
repair failure (n ¼ 2), homograft degeneration (n ¼ 3),
and progression of rheumatic disease (n ¼ 2). Tricuspid
valve surgery was required in 13 cases: annuloplasty
(n ¼ 12) and replacement with a bioprosthesis (n ¼ 1).The Journal of Thoracic and CaThe need for tricuspid valve surgery (13/35) was greater
in reoperations than at primary surgery (7/106) (P<.001).
Mortality at reoperation was 8.6% (n¼ 3/35) and not sta-
tistically higher than that of the first operation (P ¼ .39).
Causes of death were uncontrolled sepsis secondary to en-
docarditis, bleeding at sternal reentry, and left ventricular
dysfunction related to technical problems in replacing a cal-
cified aortic homograft root.
Endocarditis
Bacterial endocarditis occurred in 5 patients, who all re-
quired reoperation, and freedom from endocarditis was
95.3%. Patients initially undergoing operation for endocar-
ditis had a 10-fold higher risk (5/24) to experience a new
sepsis than patients primarily undergoing operation for an-
other cause (2/82) (P ¼ .04).
Thromboembolic and Hemorrhagic Complication
Five patients had thromboembolic complications: silent
thrombus attached to the ring (n¼ 2) and transient ischemic
attack (n ¼ 3). Two patients had severe bleeding (intramus-
cular hematoma and gastrointestinal bleeding). All patients
were treated medically. Freedom from thromboembolic/
hemorrhagic complication was 93.4%.
Functional Status
Of 51 patients alive without reoperation, functional class
according to the New York Heart Association was I
(n ¼ 37), II (n ¼ 9), and III (n ¼ 5). Thirty-five patients
were in sinus rhythm, and 16 patients were in atrial fibrilla-
tion (P ¼ .05 vs atrial fibrillation at discharge). Throughout
the study period, 9 women bearing a mitral homograft gave
birth to 15 healthy children, and there was 1 spontaneous
abortion.
Echocardiographic Study
In 5 cases, echocardiography at discharge showed grade 3
or 4 mitral regurgitation (MR), and early reoperation was
carried out. In the 92 remaining cases, baseline echography
showed a normal mitral valve function (Table 1). Left atrial
diameter and left ventricular diastolic diameter were 48.0
12 mm and 50.3  6.7 mm, respectively. Left ventricular
ejection fraction was 60%  8%. When considering sub-
categories, there was no difference in homograft valve func-
tion at discharge for age less than 40 years versus more than
40 years, partial versus total homograft, and ring size 30
mm or less versus greater than 30 mm.
Echocardiography follow-up was obtained in all 92 cases
after a mean period of 7.6  4.1 years (0.3–16.2 years). It
showed a variable degree of leaflet thickening together
with a progressively worsening regurgitant and stenotic pro-
cess. When compared with baseline data at discharge, the
degree of MR was significantly increased (Table 1). Like-
wise, transvalvular gradient was higher and surface valverdiovascular Surgery c Volume 144, Number 2 315
TABLE 1. Echocardiographic evaluation of mitral homograft valve function
Echocardiography n ¼ 92 MR grade Mean gradient (mm Hg) Valve area (cm2)
At discharge 0.4  0.5 P<.001 3.9  1.5 P<.001 2.3  0.5 P<.001
At 8.3-y follow-up 1.3þ1.2 7.0þ3.9 1.7  0.6
Age
<40 y 1.3  1.3 P ¼ .49 NS 8.1  4.2 P<.001 1.7  0.6 P ¼ .03
>40 y 1.3  1.2 5.4  2.4 1.9  0.4
Homograft technique
Total 1.4  1.2 P ¼ .07 NS 7.7  4.1 P ¼ .004 1.7  0.6 P ¼ .02
Partial 1.0  1.3 5.6  2.6 1.9  0.5
Ring size
30 mm 1.4  1.3 P ¼ .59 NS 8.2  4.1 P ¼ .002 1.6  0.5 P ¼ .002
>30 mm 1.2  1.2 5.9  3.1 1.9  0.6
NS, Not significant.
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Darea was reduced (Table 1). Mean systolic pulmonary artery
pressurewas increased (37.6 9.9 mmHg) (P¼ .001). Left
heart chamber size remained unchanged: atrial diameter:
49.0  8.4 mm (P ¼ .54), ventricular diastolic diameter:
50.8  7.3 mm (P ¼ .54), and ejection fraction: 59.1% 
8.6% (P ¼ .52).
There was no obvious parameter contributing to mitral
homograft regurgitation (Table 1). In contrast, the onset of
homograft stenosis was markedly accelerated with a higher
gradient and a smaller valve area in patients aged less than
40 years versus older patients, with a total versus partial ho-
mograft, and with a ring size 30 mm or less compared with
larger ring sizes (Table 1).
Structural Valve Deterioration
Structural deterioration was detected at explantation dur-
ing reoperation in 23 cases. With time, almost all mitral ho-
mografts showed some degree of leaflet thickening on
echocardiography. In 10 other cases, structural deterioration
was asserted by echocardiography showing gross thicken-
ing/calcification together with severe homograft dysfunc-
tion. These patients were asymptomatic, denied surgery,
or presented a contraindication due to comorbidities. Alto-
gether, structural deterioration was observed in 33 casesFIGURE 2. Cryopreserved mitral homograft explant at 14 years: Leaflet fibros
Chordae tendineae are markedly thickened, particularly at their attachment to t
316 The Journal of Thoracic and Cardiovascular Surgwith predominant insufficiency (n¼ 6), predominant steno-
sis (n ¼ 12), or mixed disease (n ¼ 15). Structural deterio-
ration was more frequent in total than in partial homografts
(P ¼ .018), in non-endocarditis than in endocarditis cases
(P ¼ .02), and in patients who were pregnant (P ¼ .016
vs no pregnancy) (Table E2). Age, ring size, and associated
aortic valve surgery did not significantly influence struc-
tural valve deterioration. Freedom from structural mitral
homograft deterioration according to the Kaplan–Meier es-
timate was 90%, 76%, and 65% at 5, 10, and 15 years, re-
spectively (Figure 1).
Histopathology
Pathologic examination of the mitral homografts ex-
planted for degeneration almost invariably showed the
same pattern; the homograft leaflets were rigid, thickened,
and calcified with no commissural fusion (Figure 2). The
samewas observed on partial homografts, but the remaining
segments of the native valve were most frequently pliable
and stenosis was less pronounced. In occasional places,
the homograft leaflet tissue was pellucid (Figure 2). The in-
volvement of the chordae was variable. Most frequently,
those were thickened and calcified particularly at their in-
sertion on the leaflets (Figure 3). Oftentimes, the proximalis with multiple calcareous nodules. In places, the leaflet tissue is pellucid.
he leaflets, whereas their proximal part is relatively spared.
ery c August 2012
FIGURE 3. Cryopreserved mitral homograft at 7 and 10 years. Left: Complete healing with fibrotic scar of the grafted muscle. The chordae are thin at their
attachment to the papillary muscle. Right: Considerable thickening with fusion and calcification of the chordae.
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mained thin. In 2 cases, rupture of accessory chordae was
observed. The attachment of the papillary muscles to the
host’s left ventricle was invariably remarkably strong
(Figure 3). The only remnant of the homograft muscles
was a fibrotic scar at the apex of the recipient’s papillary
muscles.
Microscopic analysis of the homograft leaflet tissue
showed a destruction of the normal trilaminar architecture
(Figure 4). All layers were invaded by a dense fibrosis
that was encrusted with calcium deposits. Except for 1 ex-
plant at 2 years in a child with a severe inflammatory reac-
tion, there was no sign of immune-mediated reaction in the
other valves. High magnification revealed that endothelial
cells were virtually absent and that cellularity within fibro-
sis was extremely poor (Figure 4).
DISCUSSION
Over the past decade, many isolated cases of mitral valve
homograft, particularly in those with endocarditis10,11 or in
children,12 and small series with short-term follow-up13,14
have been published. Intermediate-term results (5 years)
have been a matter of controversy. Some series in which
a prosthetic ring was parsimoniously used have reported
negative results.15,16 In contrast, mid-term results in our ex-
perience and in other groups were comparable to those of
bioprostheses in a cohort of young patients.7,17
Early valve failure as observed during the learning phase
in a few mitral homografts was related to the surgical tech-
nique and has been addressed in previous reports.6,7 The
present study was designed to assess late reoperation
focusing on structural valve deterioration. At 15 years,
one third of patients have undergone reoperation. The
most frequent indication for late reoperation wasThe Journal of Thoracic and Cadegeneration of the mitral homograft. However, a few
cases of infectious endocarditis on the homograft were
observed, particularly in those patients who primarily
underwent operation for a first episode of endocarditis
(10-fold increased risk). In some cases, reoperation was
chiefly undertaken for aortic valve disease, which often-
times had been already surgically treated. The mitral homo-
graft that was usually dysfunctioning was simultaneously
replaced. However, in 1 late reoperation, prophylactic re-
placement of a normally functioning mitral homograft
was performed to obviate the risk of secondary degradation.
From a technical standpoint, reintervention on mitral ho-
mografts was not particularly difficult. As in late reopera-
tion after repair, the prosthetic ring was removed as a first
step. Fibrocalcareous involvement of the homograft did
not raise any problem during valve apparatus excision. In
comparison, reintervention on aortic homografts is usually
more challenging18; 1 death in our series was due to techni-
cal difficulty in replacing an entirely calcified aortic homo-
graft root. Mortality of reoperation after mitral homograft
(8.6%) did not substantially differ from reported rates for
reintervention on bioprostheses.19
Kaplan–Meier freedom from reoperation was 88%,
80%, and 64% at 5, 10, and 15 years, respectively. Statis-
tical analysis of reoperation risk factors failed to identify
any determinant parameter (Table E1) except for age less
than 18 years, as suggested in a previous study,20 and pros-
thetic ring size of 28 mm.
Mitral homograft valve function was periodically as-
sessed using echocardiography. When evaluated early in
the postoperative period, mitral homograft valve function
closely mimicked that of a native valve having undergone
repair with annuloplasty (Table 1). A few years later, almost
all homografts displayed some leaflet thickening as a resultrdiovascular Surgery c Volume 144, Number 2 317
FIGURE 4. Microscopic views of a cryopreserved mitral homograft ex-
plant at 14 years. Top: Severe fibrosis with complete loss of the normal tri-
laminar architecture. Bottom: Higher magnification showing calcium
deposit (purple) amid fibrosis. Note the complete absence of cellularity
within the collagen matrix with no endothelial cell.
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idly evolving dysfunction took place resulting in a leaking
and stenotic valve. Echocardiography at the end of the study
period showed an increase in the MR grade and mean trans-
valvular gradient, and a reduction of the valve area (Table
1). Although the systolic pulmonary pressure was percepti-
bly elevated, it did not affect left ventricle size and function.318 The Journal of Thoracic and Cardiovascular SurgThe diameter of the left atrium remained unchanged
throughout the follow-up period, but the prevalence of atrial
fibrillation increased.
At 10 years, 1 of 4 mitral valve homografts was the site of
structural deterioration (Figure 1). Although the increased
rate of structural deterioration in patients aged less than
40 years did not reach statistical significance (Table E2),
the stenotic process was clearly accelerated with a higher
gradient and lower valve area compared with older patients
(Table 1). Progression toward stenosis is typical of struc-
tural deterioration and does not usually exist in endocardi-
tis. Thus, it is indisputable that degeneration of mitral
homografts occurred sooner in younger patients. The
same finding has long been reported for aortic homografts21
and bioprostheses.19
Structural valve deterioration was more frequently noted
and mitral stenosis was more pronounced in total homo-
grafts than in partial replacements (Tables 1 and E2). This
can be explained by the faster deterioration of the cryopre-
served homologous valvular tissue compared with the rem-
nants of the native valve in partial homografts. In case of
a hemivalve replacement, fibrocalcareous involvement of
the partial homograft was commonly observed, whereas
the opposite commissural area made from native tissue
was oftentimes healthy and opened widely in diastole.
The lower incidence of structural deterioration in patients
with endocarditis was probably related to the preferential
use of a partial homograft in this subgroup.
Likewise, insertion of a small ring (intercommissural dis-
tance  30 mm) was associated with a more rapidly occur-
ring stenosis (Table 1). It is difficult to discriminate the
impact of the small ring size from that of the other param-
eters; indeed, patients aged less than 40 years, which in-
cluded children, and those with a total homograft had
smaller ring size than older patients and those who received
a partial homograft.
In women of childbearing age, the choice of a mitral ho-
mograft as a valve substitute was thought to be appropriate.
The lack of oral anticoagulation clearly facilitated normal
pregnancies in this series. On the other hand, structural de-
terioration of the mitral homograft developed in two thirds
of women who experienced pregnancy (Table E2). The
same trend has been reported for bioprostheses.22
In this study, diagnosis of structural deterioration did not
rely only on the aspect of the valve at reoperation; patients
with gross leaflet thickening or calcification together with
severe dysfunction on follow-up echocardiography also
were considered.9 Altogether, freedom from structural dete-
rioration of the mitral homograft was 76% at 10 years. In
comparison, freedom from structural deterioration of mitral
bioprostheses in the study by Jamieson and colleagues19
was 60% for porcine and 80% for pericardial bioprostheses
at 10 years in patients aged less than 40 years. Tanaka and
colleagues23 reported lower freedom from structuralery c August 2012
FIGURE 5. Echocardiography in mitral homograft degeneration. Left: Progression of leaflet degeneration with time; leaflet thickening is already visible at
8 years and then dramatically worsens by 14 years. Right: Hyperechogenicity of the grafted papillary muscle after partial mitral homograft with normal
aspect of the opposite muscle. LV, Left ventricle; LA, left atrium.
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only structural valve deterioration noted at reoperation was
considered (no inclusion on echocardiography criteria).
Thus, the structural deterioration rate of mitral homografts
seems comparable to that of the best existing biological
valve substitutes. Nevertheless, because the implantation
technique of the mitral homograft is more challenging and
carries a risk of early failure that does not exist with bio-
prostheses, its use cannot be recommended until a more pro-
longed durability can reasonably be expected. In our own
practice over the past decade, mitral homografts have sel-
dom been used whenever biological mitral valve replace-
ment was needed and bioprostheses were preferred.
CONCLUSIONS
Pathologic findings on mitral homografts explanted for
degeneration are in agreement with observations reported
for aortic homografts.24 Valve tissue was invaded by a dense
fibrosis with a complete loss of the normal trilaminar archi-
tecture and scattered with calcium deposits. Except for 1
early explant, which was the site of a severe inflammatory
reaction, in a child, the homograft tissue was virtually acel-
lular with no sign of immune-mediated injury. These obser-
vations suggest that the actual cryopreservation process
used for storing valvular homografts profoundly alters cel-
lular components of the endothelium and collagen matrix.
As opposed to the proponents of the immune-induced de-
generation theory, we believe that cell viability is an essen-
tial prerequisite for valve tissue regeneration. Future
direction to extend the longevity of mitral homografts
would call for an improvement in the cryopreservation
method (temperature, type, and concentration of cryopro-
tective agents). Alternatively, as suggested by the remark-
able lack of valve deterioration in heart transplant
recipients,25 the use of ultra-fresh homografts inserted
within 24 hours after harvesting could be advocated.
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TABLE E1. Determinants of reoperation in 106 patients with a mitral
homograft
Reoperation n ¼ 35 n % P
Age
<40 y 20/57 36.8% P ¼ .46 NS
>40 y 15/49 30.6%
Homograft technique
Total 26/66 39.4% P ¼ .07 NS
Partial 9/40 22.5%
Ring size
30 mm 18/49 36.7% P ¼ .45 NS
>30 mm 17/57 29.8%
Associated aortic valve surgery
Yes 7/15 46.7% P ¼ .23 NS
No 28/91 30.8%
Endocarditis as primary indication
Yes 6/24 25.0% P ¼ .34 NS
No 29/82 35.3%
Pregnancy
Yes 3/9 33.3% P ¼ .98 NS
No 32/97 40.0%
NS, Not significant.
TABLE E2. Determinants of structural valve deterioration in 106
patients with a mitral homograft
Structural valve
deterioration N ¼ 33 n % P
Age
<40 y 21/57 36.8% P ¼ .17 NS
>40 y 12/49 24.5%
Homograft technique
Total 26/66 39.3% P ¼ .018
Partial 7/40 17.5%
Ring size
30 mm 13/49 26.5% P ¼ .34 NS
>30 mm 20/57 35.1%
Associated aortic valve surgery
Yes 4/15 26.6% P ¼ .68 NS
No 29/91 31.9%
Endocarditis as primary indication
Yes 3/24 12.5% P ¼ .02
No 30/82 36.6%
Pregnancy
Yes 6/9 66.7% P ¼ .016
No 27/97 27.8%
NS, Not significant.
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